Koers Gene Biotherapeutics, Inc. Other OTC
Aandelen
CRXM
US8767671048
Biotechnologie & Medisch Onderzoek
Omzet 2019 | - | Omzet 2020 | - | Marktkapitalisatie | 551K 515K |
---|---|---|---|---|---|
Nettowinst (verlies) 2019 | - 0 | Nettowinst (verlies) 2020 | - 0 | EV/omzet 2019 | - |
Nettoschuld 2019 | 1,12 mln. 1,05 mln. | Nettoschuld 2020 | 874K 818K | EV/omzet 2020 | - |
K/w-verhouding 2019 |
3,09
x | K/w-verhouding 2020 |
-1,77
x | Werknemers | - |
Dividendrendement 2019 * |
-
| Dividendrendement 2020 |
-
| Vrij verhandelbaar | 93,84% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 70 | 22-12-03 | |
James Grainer
CHM | Chairman | 69 | 22-05-20 |
Lois Chandler
COO | Chief Operating Officer | - | 01-07-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 70 | 22-12-03 | |
James Grainer
CHM | Chairman | 69 | 22-05-20 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22-05-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |